{
    "clinical_study": {
        "@rank": "149911", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have\n      recurrent or metastatic non-small cell lung cancer."
        }, 
        "brief_title": "R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "July 2007", 
            "@type": "Actual"
        }, 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Assess the response rate of patients with recurrent or metastatic non-small cell lung\n           cancer when treated with tipifarnib.\n\n        -  Determine the clinical toxicities of this treatment in these patients.\n\n        -  Assess the overall survival and time to progression of this patient population when\n           treated with this regimen.\n\n        -  Evaluate the inhibition of protein farnesylation in vivo and correlate such inhibition\n           to plasma levels of tipifarnib.\n\n        -  Evaluate the occurrence of CYP450 polymorphisms and relate these to drug toxicity,\n           pharmacokinetics, and response to this treatment in this patient population.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days\n      in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 3 months for 5 years.\n\n      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study over 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed recurrent or metastatic non-small cell lung\n             cancer (NSCLC)\n\n          -  Measurable disease\n\n               -  At least 20 mm in at least one dimension\n\n               -  Nonmeasurable is defined as any of the following:\n\n                    -  Bone lesions\n\n                    -  Leptomeningeal disease\n\n                    -  Ascites\n\n                    -  Pleural/pericardial effusion\n\n                    -  Inflammatory breast disease\n\n                    -  Lymphangitis cutis/pulmonis\n\n                    -  Abdominal masses not confirmed and followed by imaging techniques\n\n                    -  Cystic lesions\n\n          -  No CNS metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age\n\n          -  18 and over\n\n        Performance status\n\n          -  ECOG 0-2\n\n        Life expectancy\n\n          -  At least 12 weeks\n\n        Hematopoietic\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic\n\n          -  Bilirubin no greater than 2 times upper limit of normal (ULN)\n\n          -  AST no greater than 3 times ULN (no greater than 5 times ULN in case of hepatic\n             metastases)\n\n        Renal\n\n          -  Creatinine no greater than 2 times ULN\n\n        Cardiovascular\n\n          -  No New York Heart Association class III or IV heart disease\n\n        Other\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No uncontrolled infection\n\n          -  No other prior malignancy in past 5 years except adequately treated basal cell or\n             squamous cell skin cancer or other adequately treated noninvasive carcinomas\n\n          -  No other concurrent severe underlying disease\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy\n\n          -  No prior biologic, gene, or immunotherapy\n\n        Chemotherapy\n\n          -  No prior chemotherapy for NSCLC except low dose cisplatin as radiosensitizer\n\n        Endocrine therapy\n\n          -  Not specified\n\n        Radiotherapy\n\n          -  Prior radiotherapy to less than 25% of bone marrow allowed\n\n        Surgery\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "July 5, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005989", 
            "org_study_id": "CDR0000067978", 
            "secondary_id": [
                "U01CA069912", 
                "P30CA015083", 
                "982401"
            ]
        }, 
        "intervention": {
            "intervention_name": "tipifarnib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tipifarnib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "recurrent non-small cell lung cancer", 
            "stage IV non-small cell lung cancer"
        ], 
        "lastchanged_date": "August 2, 2011", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MAYO-982401"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Mayo Clinic in Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago Cancer Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non-Small Cell Lung Cancer", 
        "overall_official": [
            {
                "affiliation": "Mayo Clinic", 
                "last_name": "Julian Molina, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Mayo Clinic", 
                "last_name": "Elizabeth Johnson, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2007", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005989"
        }, 
        "responsible_party": {
            "name_title": "Julian R. Molina, M.D., Ph.D.", 
            "organization": "Mayo Clinic Cancer Center"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2002", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2011"
    }, 
    "geocoordinates": {
        "Mayo Clinic": "44.022 -92.47", 
        "Mayo Clinic in Florida": "30.332 -81.656", 
        "University of Chicago Cancer Research Center": "41.878 -87.63"
    }
}